People / Staff

Jaume Mora Graupera

Search publications

Publications

  • Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N.

    Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues

    CANCER DISCOVERY . 14(6): 953-964.

    [doi:10.1158/2159-8290.CD-23-1186]

  • Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.

    Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.

    Frontiers in oncology . 14: 1380917-1380917.

    [doi:10.3389/fonc.2024.1380917]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): .

    [doi:10.3390/cancers16091735]

  • Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.

    Current Status of Fertility Preservation in Pediatric Oncology Patients.

    CHILDREN-BASEL . 11(5): .

    [doi:10.3390/children11050537]

  • Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.

    GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

    INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Number of citations: 1

    [doi:10.1002/ijc.34815]

  • Llurba E, Fàtima Crispi Brillas, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.

    Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.

    BMJ Open . 14(3): .

    [doi:10.1136/bmjopen-2023-076201]

  • Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.

    Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model

    Cancers . 16(5): .

    [doi:10.3390/cancers16051060]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Number of citations: 4

    [doi:10.3390/cancers15194837]

  • Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.

    EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping

    iScience . 26(9): 107598-107598.

    [doi:10.1016/j.isci.2023.107598]

  • Cristina Larrosa Espinosa, Mora J and Cheung NK.

    Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2

    Cancers . 15(14): . Number of citations: 3

    [doi:10.3390/cancers15143729]